Intezyne Technologies Granted Orphan Drug Designation for IT-139 in Pancreatic Cancer

By WebmasterJune 20, 2017November 1st, 2024No Comments

Intezyne Technologies Granted Orphan Drug Designation for IT-139 in Pancreatic Cancer

Previous PostDr. Ottavio Vitolo Appointed Executive Clinical Advisor at Relmada Therapeutics
Next PostCharles J. Casamento Appointed Chairman of Relmada Therapeutics Board of Directors